Brain Trust: Conversations in Psychopharmacology
Joseph F. Goldberg, MD, hosts discussions with experts in clinical psychopharmacology on topics that are front of mind, controversial, unresolved, or should be part of clinical thinking for prescribers. The podcast evaluates what is topical in psychopharmacology and what clinicians need to know.
Episodes
9: How to Prescribe Off-Label With Henry Nasrallah, MD
Joseph F. Goldberg, MD, in this installment of "Brain Trust: Conversations in Psychopharmacology," sits down with Henry Nasrallah, MD, to discuss off-label prescribing and polypharmacy.Nasrallah bases the discussion off his landmark analysis that demonstrated 88% of DSM psychiatric diagnoses have no US Food and Drug Administration (FDA)-approved pharmacotherapy, leaving clinicians with no choice
8: Early Intervention & Psychopharmacology in Bipolar Disorder With Robert M. Post, MD
Joseph F. Goldberg, MD, in this installment of "Brain Trust: Conversations in Psychopharmacology," sits down with Robert M. Post, MD, to discuss evolving perspectives on bipolar disorder and treatment, emphasizing early intervention and the underutilization of lithium.There is a high prevalence of childhood-onset bipolar disorder in the United States, noted Post, with approximately a quarter of c
7: The Role of Psychopharmacology in Pediatric Care: Discussing Strategies With Melissa DelBello, MD
Joseph F. Goldberg, MD, in this installment of "Brain Trust: Conversations in Psychopharmacology," sits down with child and adolescent psychiatrist Melissa DelBello, MD, to discuss the role of psychopharmacology in pediatric mental health treatment. Their conversation emphasized early identification and intervention for mood and related disorders in young patients.DelBello addressed common concer
6: The Complex Psychopharmacology of Personality Disorders: Prioritizing Symptom Management With Michael Gitlin, MD
Joseph F. Goldberg, MD, in this installment of "Brain Trust: Conversations in Psychopharmacology," sits down with Michael Gitlin, MD, to discuss psychopharmacologic options for personality disorders.They highlighted the dimensional nature of personality disorders, contrasting them with the categorical DSM model.“The relationship between treating personality disorders and the use of medicines is n
5: Pharmacogenetic Testing in Psychiatry: Exploring Personalized Medicine With John J. Miller, MD
Joseph F. Goldberg, MD, in this installment of "Brain Trust: Conversations in Psychopharmacology," sits down with Psychiatric Times' very own editor in chief, John J. Miller, MD, to discuss the current state and future directions of pharmacogenetic testing.According to Goldberg, pharmacogenetics is almost like a Rorschach test in the eyes of many practitioners and patients: “It is thought to be a
4: Psychedelics for Depression and Other Mental Health Conditions: The Way Forward With Guy Goodwin, MD
Joseph F. Goldberg, MD, in this installment of "Brain Trust: Conversations in Psychopharmacology," sits down with Guy Goodwin, MD, to discuss the potential of psychedelics in treating depression and other mental health conditions. Goodwin, who is the chief medical officer at Compass Pathways, highlights psilocybin's ability to induce profound experiences that can lead to long-term improvements in
3: The Intersection of Psychotherapy and Psychopharmacology for Mood Disorders: Optimizing Patient Outcomes With Holly A. Swartz, MD
Joseph F. Goldberg, MD, in this installment of "Brain Trust: Conversations in Psychopharmacology," sits down with Holly A. Swartz, MD, to discuss evidence-based psychotherapies for mood disorders, emphasizing a nuanced approach to treating depression. If a patient prefers to start with psychotherapy, they should be given 6 to 12 weeks to see if it works before considering augmentation or switchin
2: The Role of GLP-1s in Psychiatry: Learning More With Roger S. McIntyre, MD, FRCPC
Joseph F. Goldberg, MD, in this installment of "Brain Trust: Conversations in Psychopharmacology," sits down with Roger S. McIntyre, MD, FRCPC, to discuss glucagon-like peptide-1 (GLP-1) agonists and their role in psychiatry. McIntyre highlights the transformative impact of GLP-1 agonists on weight and glucose management. GLP-1s are "truly transformative," McIntyre says, as they affect the brain
1: Depression, SSRIs, and Pregnancy: Getting to the Truth With Marlene P. Freeman, MD
Joseph F. Goldberg, MD, in his first installment of "Brain Trust: Conversations in Psychopharmacology," sits down with Marlene P. Freeman, MD, to discuss the treatment of depression, selective serotonin reuptake inhibitors (SSRIs), and pregnancy. On July 21, 2025, the US Food and Drug Administration led an expert panel on SSRIs and pregnancy, in which they questioned the validity of psychiatric m
Recommended
1Dime Radio
오늘 미국은
$100M Offers by Alex Hormozi, Book Summary, Podcast, English
0xResearch
10000 MINUTES
1000 Things You Should Know
1000x
1001 Classic Short Stories & Tales
1001raah | هزار و یک راه
1001 Sherlock Holmes Stories & The Best of Sir Arthur Conan Doyle
1001 Songs That Make You Want To Die
100 Famous Dogs
